Entomon
Entomon S.R.L., an Italian Stallergenes Greer subsidiary, produces high-purity Hymenoptera venom extracts via its proprietary Capillary Extracted Venom® process for pharmaceutical manufacturers making allergy diagnostics and venom immunotherapy vaccines.
- Company typePrivate
- Founded-
- HeadquartersItaly, United States
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
Entomon firmographics
Firmographics- Name
- Entomon
- Legal name
- Entomon S.R.L.
- Website
- https://entomon.it
- Company type
- Private
- Operating status
- Operating
- Short description
- Entomon S.R.L., an Italian Stallergenes Greer subsidiary, produces high-purity Hymenoptera venom extracts via its proprietary Capillary Extracted Venom® process for pharmaceutical manufacturers making allergy diagnostics and venom immunotherapy vaccines.
- Ownership category
- akta.pro rank
Entomon industry classification
Industry- Product category
- Pharmaceutical Raw Materials (Hymenoptera Venom)
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Allergy Immunotherapy Biologics (allergen extracts, desensitization) (HLAAAEAI)
Keywords
Where Entomon is headquartered
LocationHeadquarters
- HQ city
- Italy
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Entomon business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Venom raw material sales: Entomon produces and sells high-purity Hymenoptera venom extracts as raw materials to pharmaceutical companies for the production of diagnostic preparations and vaccines for people allergic to insect stings.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Entomon product offering
Product offeringCore offering
Entomon produces and supplies high-purity, lyophilized Hymenoptera venoms (honey bee, bumblebee, wasp, and hornet species) as raw materials to pharmaceutical companies. The venoms are extracted using the proprietary registered "Entomon Capillary Extracted Venom®" technique, which collects venom directly from the venom sac without further purification, and are used by customers to manufacture diagnostic preparations and venom immunotherapy vaccines for people allergic to insect stings.
Product overview
Entomon produces high-purity Hymenoptera venoms as raw material for the pharmaceutical industry, using its proprietary registered Entomon Capillary Extracted Venom® extraction technique. The product portfolio consists of six capillary-extracted venom products for diagnostics and therapeutics (from Apis mellifera, Bombus terrestris, Polistes dominula, Vespula germanica-vulgaris, Vespa crabro, and Vespa velutina nigrithorax), one crude Apis mellifera venom for external use obtained via electostimulation, and lyophilized extracts of other arthropods for scientific research. All venom products undergo manual extraction, protein quantification, lyophilization, and storage at -20°C, with each batch released with a Certificate of Analysis and Technical Data Sheet.
Differentiator
Problem solved
Functional benefit
Products and services
- Capillary Extracted Venom — Apis mellifera
Quantifiable outcome
- 95-98% success rate in treated cases for venom immunotherapy
Companies that use Entomon
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles2 records
Entomon technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Entomon partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Stallergenes Greerparent companyEntomon s.r.l. is a company of the Stallergenes Greer group. Stallergenes Greer is a pharmaceutical company specializing in allergy treatments and diagnostics.
Scale indicators2 records
Recent moves5 records
Expansion highlights4 records
Entomon competitors and assessment
Company assessmentEmerging players
- Biomay: Austrian manufacturer of recombinant and native allergen products for allergy immunotherapy and diagnostics. Comparable as a producer of allergen raw materials and finished extracts that compete with Entomon's downstream customers.
- INDOOR Biotechnologies: US-based manufacturer of purified native and recombinant allergens for allergy research, diagnostics, and therapeutics. Comparable as a specialist allergen extract producer serving pharmaceutical customers with overlapping species coverage.
Direct peers
- Allergy Therapeutics: UK-based specialty pharmaceutical company developing and commercializing allergy vaccines and diagnostics. Comparable to Entomon's customers, with overlapping focus on Hymenoptera venom-based immunotherapy.
- HAL Allergy: European allergy immunotherapy company producing diagnostic and therapeutic allergen extracts, including Hymenoptera venoms. Directly comparable as a vertically integrated allergy immunotherapy specialist competing for the same end customers.
- ALK-Abelló: Danish global leader in allergy immunotherapy with in-house allergen and venom sourcing for diagnostics and vaccines. ALK is the most direct competitor to Entomon's downstream customers and a parallel operator in the venom raw-material value chain.
Broad incumbents
- Stallergenes Greer: Entomon's parent company and a global leader in allergy immunotherapy and diagnostics. As both customer and corporate parent, Stallergenes Greer is the most directly comparable incumbent and shapes Entomon's commercial roadmap.
Regional players
- LETI Pharma: Spanish allergy immunotherapy and diagnostics company producing allergen extracts including Hymenoptera venoms for European and Latin American markets. Comparable in product focus and customer base, though geographically distinct.
- Roxall Group: German allergy immunotherapy company with a portfolio of allergen diagnostics and immunotherapies, including insect venom products. Comparable in scope of allergen offerings and customer overlap within European markets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Entomon compliance and trust
Trust signalCompliance1 record
Entomon financial estimates
Financial estimateRevenue estimate
Valuation estimate
Entomon leadership team
Management profileNumber of profiles
Profiles5 records
Entomon funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Entomon M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Entomon
What does Entomon do?
Entomon produces and supplies high-purity, lyophilized Hymenoptera venoms (honey bee, bumblebee, wasp, and hornet species) as raw materials to pharmaceutical companies. The venoms are extracted using the proprietary registered "Entomon Capillary Extracted Venom®" technique, which collects venom directly from the venom sac without further purification, and are used by customers to manufacture diagnostic preparations and venom immunotherapy vaccines for people allergic to insect stings.
Is Entomon a public or private company?
Entomon is a private company. It is classified as corporate owned and is currently operating.
When was Entomon founded?
Entomon was founded in -1.
Where is Entomon based?
Entomon is headquartered in Italy, United States, in the North America region.
How does Entomon make money?
One revenue line is on record: venom raw material sales.
Who are Entomon's main competitors?
Emerging players on record are Biomay and INDOOR Biotechnologies. Direct peers are Allergy Therapeutics, HAL Allergy and ALK-Abelló. Stallergenes Greer is listed as a broad incumbent. Regional players are LETI Pharma and Roxall Group.
Does Entomon have an API?
No public API is recorded for Entomon.
What industry is Entomon in?
Entomon's product category is Pharmaceutical Raw Materials (Hymenoptera Venom). Its primary akta.pro industry code is HLAAAEAI, Allergy Immunotherapy Biologics (allergen extracts, desensitization). Its NAICS code is 325414 and its SIC code is 2836.